Generic and Hybrid Veterinary Medicines: Articles 18 and 19 Compared

A generic veterinary medicine can rely on the reference product’s data, but only if it truly behaves like a generic. When it does not, Regulation (EU) 2019/6 treats it as a hybrid and asks for additional studies. Picking the wrong route costs months.

The two routes

Article 18 allows an applicant for a generic to refer to the technical documentation of a reference product. Article 19 deals with products that do not have all the characteristics of a generic. For those, the applicant must provide results of pre-clinical studies or clinical trials as needed.

When a product becomes a hybrid

According to Article 19(1), additional studies are required where:

  • the active substance, indications, strength, pharmaceutical form or route of administration differs from the reference product;
  • bioavailability studies cannot demonstrate bioequivalence with the reference product; or
  • for a biological product, the raw materials or manufacturing processes differ from those of the reference biological product.

The scope of the extra data should be justified by the difference, so a change in route may call for different evidence than a change in strength. It is wise to agree this in advance with the authority through scientific advice or early contact.

Which reference product

Article 19(2) allows studies for a hybrid to use batches of a reference product authorised in the Union or in a third country. For a third-country reference, the applicant must show that it was authorised under equivalent requirements and that the two products are highly similar so they can substitute each other in the clinical trials.

Timing and exclusivity

A reference product’s technical documentation is protected from the day of its authorisation. Article 39 sets the protection periods: 10 years for cattle, sheep for meat production, pigs, chickens, dogs and cats; 14 years for antimicrobials with a new active substance in those species, and for other species; and 18 years for bees. A generic cannot be authorised on the strength of the reference data until the period has expired, so the calendar belongs in the plan from the outset.

Typical pitfalls

  • Treating a new route or form as a simple line extension of a generic.
  • Bioequivalence studies run in the wrong species or population.
  • No justification for any excipient differences.
  • Overlooking the environmental risk assessment for a hybrid with a different use pattern.

Planning the development programme

The earlier the classification is clear, the better the programme can be designed. A short regulatory strategy memo should record the reference product, the proposed differences, the planned studies and the reasoning for each. Where the difference is small, an authority may accept a limited package, but this should be tested before expensive studies begin. Equally, it is worth confirming which procedure and which Member States are intended, since the choice affects timelines and the handling of national questions.

  • Document the reference product and its authorisation date.
  • Agree the scope of additional data with the authority where possible.
  • Prepare the environmental and residue sections, which are often overlooked.

How PQRA helps

PQRA can assess your product against the generic and hybrid criteria, identify the supporting data you will need, check the data protection timeline for your reference product and prepare the application for submission.

Questions about this topic? Contact PQRA to discuss your veterinary portfolio.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *